Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models.

ABSTRACT:

Background

Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive malignancy with only a 5% 5-year survival rate. Reliable biomarkers for early detection are still lacking. The goals of this study were (a) to identify early humoral responses in genetically engineered mice (GEM) spontaneously developing PDAC; and (b) to test their diagnostic/predictive value in newly diagnosed PDAC patients and in prediagnostic sera.

Methods and results

The serum reactivity of GEM from inception to invasive cancer, and in resectable or advanced human PDAC was tested by two-dimensional electrophoresis Western blot against proteins from murine and human PDAC cell lines, respectively. A common mouse-to-human autoantibody signature, directed against six antigens identified by MALDI-TOF ma

SUBMITTER: Capello M 

PROVIDER: S-EPMC3844582 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature